22.11.2016 • NewsElaine BurridgeBiogasDuPont

DuPont Supplies Enzymes to Miavit

(c) photosbyjim/Getty Images
(c) photosbyjim/Getty Images

DuPont Industrial Biosciences will supply its Fibrezyme G4 enzymes to Miavit, a German provider of feedstuffs, supplement, minerals and vitamins. Miavit will use the enzymes in MiaMethan ProCut, its new biogas ingredient for the agricultural sector. Fibrezyme G4 is said to help reduce the viscosity of poorly digestible materials by more than 60%, thus allowing faster processing time.

“As new technology like Fibrezyme comes online, we see tremendous opportunity for our customers to improve efficiency and yields. This, in turn, provides the emerging biogas industry a new revenue stream, particularly for rural and farm communities, from materials that would ordinarily go to waste – reducing damaging environmental impacts and expanding renewable options for power generation,” said Franz Otten, Miavit’s managing director of sales.

Enzymes work by accelerating the breakdown of various materials, such as plant fibers and animal and food waste, into sugars and amino acids, which are more suitable for conversion into biogas. Methane biogas is primarily used to generate renewable electricity, or is compressed and inserted into the gas pipeline grid.

DuPont entered the growing biogas sector in July of this year with the launch of Optimash AD-100, a liquid enzyme that can increase biogas yields in anaerobic digesters by as much as 13%. Fibrezyme G4 was originally launched by Florida-based biotechnology company Dyadic in April 2014. Dyadic sold its industrial technology assets to DuPont Industrial Biosciences for $75 million in January 2016, having decided to focus exclusively on its biopharmaceutical business.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.